knowledge -WSS

knowledge

author：leisure time 2025-10-01 20:14:17 - browse：6

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

WSS

New safety details link Apellis eye drug to rare cases of blindness

Study on Amgen’s bispecific immunotherapy produces positive data

STAT Summit: How researchers deal with rejection

STAT Summit: The economic case for universal basic health care

Physician groups backed by private equity giant lobby on mergers

UnitedHealth, Optum discontinue NaviHealth name

Wikipedia

knowledge

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Roche drug slashes death risk in early

After affirmative action ruling, medical educators look to 'holistic review'

Trump indictment: Who are the 'co

Peter Hotez and the public health issue of online harassment

New safety details link Apellis eye drug to rare cases of blindness

Medicare proposal to cover medical devices draws a mixed reaction

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

United colonoscopy coverage change 'may cost lives,' doctors say

Physician groups backed by private equity giant lobby on mergers

leisure time

Cassava Sciences’ Alzheimer’s clinical trials should be halted

STAT Readout Newsletter: Biotech news today

Roivant's CEO is a star, but biotech's black hole persists

Physician groups backed by private equity giant lobby on mergers

Smaller biotechs seek to piggyback on weight loss drug boom

UnitedHealth, Optum discontinue NaviHealth name

entertainment

hotspot

leisure time

hotspot